Home›Treatments›Allergy›Avamys

Avamys Nasal Spray

Avamys is a prescription-only nasal spray containing the active ingredient fluticasone furoate, a corticosteroid. It is used to treat the symptoms of allergic rhinitis (hay fever), such as sneezing, a blocked or runny nose, and itching in the nose. This treatment works directly in the nose to reduce inflammation caused by an allergic reaction to allergens like pollen, dust mites, or pet dander. If you are struggling with hay fever or allergy symptoms, Avamys can provide targeted, effective relief when used as directed by a clinician.                 

Complete a short online consultation so our prescriber can confirm the treatment suits you.
The decision to supply the specific treatment and quantity requested will be based on whether our medical team are satisfied that it will be safe, appropriate, and effective.
Or 3 interest-free payments of £7.33 via Klarna
Tracked 24 Delivery3 interest-free payments via KlarnaDiscreet packaging

Avamys Treatment

Product NameAvamys
ManufacturerGlaxoSmithKline UK Ltd
Active IngredientFluticasone furoate
AdministrationIntranasal spray
PresentationAqueous nasal spray suspension
Available Strengths27.5mcg / 1 Bottle x 120 doses
Product TypePOM — Prescription Only
Link to Patient Information LeafletAvamys PIL ↗

Avamys Pricing

Package typePriceAvailability
27.5mcg / 1 Bottle x 120 doses£21.99In stock
Authored byNabeel

Medical Content Officer

Nabeel is a co-founder, and medical content officer of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.

Medical Doctor

Dr. Talal is a GMC registered doctor and medical content reviewer at Chemist Doctor. He ensures clinical accuracy and reliability across health content.

Approved byUsman

Medical Administrative Officer

Usman is a co-founder, and medical administrative officer of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical administration and operational priorities.

Review Date: 2 Jul 2026

Next Review: 1 Jan 2027

Published on: 19 Nov 2025

Last Updated: 3 Jul 2026